Giant Cell Arteritis Market Research
What is Giant Cell Arteritis (GCA)?
Giant cell arteritis (GCA), also known as temporal arteritis, is a type of vasculitis or inflammation of the arteries. While GCA primarily occurs in the arteries within the temples, the inflammatory condition can affect the entire head, scalp, neck, and arms. The linings of the arteries become inflamed, in turn causing swelling and limiting the amount of blood reaching the head. GCA typically affects those over 50 years old (mostly above 65 years) and commonly occurs in women. Symptoms of GCA include: severe headaches, pain in the temples, scalp pain and tenderness, sudden weight loss, loss of appetite, jaw pain, dizziness, double vision, neck stiffness, fever, and fatigue. Left untreated, GCA can lead to aneurysms, blindness, and (while uncommon) strokes. Roughly half of patients experiencing GCA also experience symptoms associated with polymyalgia rheumatica (PMR). Treatments for GCA include glucocorticoids and Genentech’s Actemra (tocilizumab), as it is currently the only available advanced systemic treatment for the indication.
Spherix Global Insights – Rheumatology – Giant Cell Arteritis (GCA)
Spherix Global Insights’ rheumatology therapeutic team is a leading provider of independent syndicated giant cell arteritis market research, insights, business intelligence & advisory services.
Spherix’s rheumatology team publishes one (1) study in GCA:
- Market Dynamix™: Giant Cell Arteritis (US)
Spherix’s Market Dynamix™ service includes analysis of markets anticipated to experience a paradigm shift within the next three to five years. Its insights highlight market size, current treatment approaches, unmet needs, and expert opinions on the likely disruption introduced by pipeline agents.
Follow Spherix Rheumatology on Social Media
For Guests & Current Clients
For more details on Spherix’s primary market research reports and interactive dashboard offerings, visit or register here: